DNA RNA and Cells

07 Jul 2017 Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A
07 Jul 2017 Sanofi Genzyme and Alnylam Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B with or without Inhibitors
06 Jul 2017 Inovio’s DNA-based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation
05 Jul 2017 Health for Life Capital™ Participates in $13.2m Financing of Japanese Microbiome Leader Anaeropharma Science
04 Jul 2017 NOXXON announces first patients treated in phase I/II clinical trial of NOX-A12 combined with Keytruda® in metastatic pancreatic and colorectal cancer
03 Jul 2017 Promethera Announces Review Acceptance of Heparesc New Drug Submission for Neonatal Onset Urea Cycle Disorders by Health Canada
30 Jun 2017 eTheRNA Immunotherapies Advances In-Vivo mRNA Cancer Immunotherapy into First Oncology Clinical Studies
30 Jun 2017 New Data Reaffirm Clinically Meaningful Benefit of SPINRAZA® (nusinersen) in Individuals with Spinal Muscular Atrophy Across Disease Severity
28 Jun 2017 First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital
27 Jun 2017 Crestovo Doses Patients in PRISM 3, a Clinical Trial of CP101, a Microbiome Therapy for the Prevention of Recurrent Clostridium difficile Infection
27 Jun 2017 bluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D™ Drug Product in Cerebral Adrenoleukodystrophy (CALD)
26 Jun 2017 Alnylam Reports New Positive Clinical Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
23 Jun 2017 bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease (SCD) at European Hematology Association (EHA) Annual Meeting
23 Jun 2017 bluebird bio Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobinTM Drug Product at European Hematology Association (EHA) Annual Meeting
23 Jun 2017 Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
23 Jun 2017 mRNA Vaccines & Therapeutics: are you ready to be on the ground floor of the next big new therapeutic modality?
22 Jun 2017 Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease Completed and Open-Label Extension Study to Open in 2H 2017
21 Jun 2017 Celyad reports promising early results at first dose level of the solid arm of the THINK trial
21 Jun 2017 Synlogic™ Doses First Subject in Phase 1 Trial of Novel Class of Synthetic Biotic™ Medicines
21 Jun 2017 Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR707 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Lymphoma
21 Jun 2017 Cell Medica acquires WT1 cancer immunotherapy from Cell and Gene Therapy Catapult
20 Jun 2017 Seattle Genetics Discontinues Phase 3 CASCADE Trial of Vadastuximab Talirine (SGN-CD33A) in Frontline Acute Myeloid Leukemia
20 Jun 2017 TCR2 Therapeutics Presents Positive Solid Tumor Data for its Novel TRuC™ Engineered T Cell Therapies at the World Preclinical Congress
19 Jun 2017 TxCell appoints Lentigen Technology, Inc. to manufacture the lentiviral vector for its first CAR-Treg program in transplant rejection
18 Jun 2017 Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data at International Conference on Malignant Lymphoma

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing